Endothelial progenitor cells: past, state of the art, and future

被引：77

作者：

Iwami, Y

Masuda, H

Asahara, T ^{[1
]}

机构：

[1] Tokai Univ, Sch Med, Dept Regenerat Med Sci, Isehara, Kanagawa 2591193, Japan

[2] Kobe Inst Biomed Res, Stem Cell Translat Res & Innovat, Kobe, Hyogo, Japan

[3] RIKEN, Ctr Dev Biol, Chuo Ku, Kobe, Hyogo, Japan

来源：

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE | 2004年 / 8卷 / 04期

关键词：

endothelial progenitor cell (EPC); vasculogenesis; angiogenesis; therapeutic neovascularization; cardiovascular disease; cell therapy;

D O I：

10.1111/j.1582-4934.2004.tb00473.x

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Recent evidences suggest that endothelial progenitor cells (EPCs) derived from bone marrow (BM) contribute to de novo vessel formation in adults occurring as physiological and pathological responses. Emerging preclinical trials have shown that EPCs home to sites of neovascularization after ischemic events in limb and myocardium. On the basis of these aspects, EPCs are expected to develop as a key strategy of therapeutic applications for the ischemic organs. Such clinical requirements of EPCs will tentatively accelerate the translational research aiming at the devices to acquire the optimized quality and quantity of EPCs. In this review, we attempt to discuss about biological features of EPCs and speculate on the clinical potential of EPCs for therapeutic neovascularization.

引用

页码：488 / 497

页数：10

共 41 条

[1] Isolation of putative progenitor endothelial cells for angiogenesis [J].